Brain–Computer Interface Improves Symptoms of Isolated Focal Laryngeal Dystonia: A Single‐Blind Study
Movement Disorders · 2026
DOI: 10.1002/mds.70114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, 2026. Verfasst von Stefan K Ehrlich und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Brain-Computer Interfaces, Dystonic Disorders, Neurofeedback, Laryngeal Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS, NINDS NIH HHS, National Institute on Deafness and Other Communication Disorders.
Abstract (Originalsprache)
Background and objective Laryngeal dystonia (LD) is a focal task‐specific dystonia, affecting speaking but not whispering or emotional vocalizations. Therapeutic options for LD are limited. We developed and tested a non‐invasive, closed‐loop, neurofeedback, brain–computer interface (BCI) intervention for LD treatment.
Methods
Ten patients with isolated focal LD participated in the study. The personalized BCI system included visual neurofeedback of individual real‐time electroencephalographic (EEG) activity during symptomatic speaking compared to asymptomatic whispering, presented in the virtual reality (VR) environment of real‐life scenarios. During five consecutive days of intervention, patients used the BCI to learn to modulate their abnormally increased brain activity during speaking and match it to near‐normal activity of asymptomatic whispering. Changes in voice symptoms and EEG activity were quantified for the evaluation of BCI effects.
Results
Compared to baseline, LD patients had a statistically significant reduction of their voice symptoms on Days 1–5 of BCI intervention. Thi was paralleled by improved controllability of the visual neurofeedback and a significant reduction of left frontal delta power, including superior and middle frontal gyri, on Day 1 and left central gamma power, including premotor, primary sensorimotor, and inferior parietal areas, on Days 3 and 5. The majority of patients (70%) reported sustained positive effects of the BCI intervention on their voice quality 1 week after the study participation.
Conclusion
The closed‐loop BCI neurofeedback intervention specifically targeting disorder pathophysiology shows significant potential as a novel treatment option for patients with LD and likely other forms of task‐specific focal dystonia. © 2025 International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Speech Pathology, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Queensland, Australia.
- Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Kristina Simonyan
Förderung
- NIDCD NIH HHS
- NINDS NIH HHS
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Ehrlich, S. K., Tougas, G., Bernstein, J., Buie, N., Rumbach, A. F., & Simonyan, K. (2026). Brain–Computer Interface Improves Symptoms of Isolated Focal Laryngeal Dystonia: A Single‐Blind Study. Movement Disorders. https://doi.org/10.1002/mds.70114
Vancouver
Ehrlich SK, Tougas G, Bernstein J, Buie N, Rumbach AF, Simonyan K. Brain–Computer Interface Improves Symptoms of Isolated Focal Laryngeal Dystonia: A Single‐Blind Study. Movement Disorders. 2026. doi:10.1002/mds.70114
BibTeX
@article{Ehrlich2026,
author = {Ehrlich, Stefan K and Tougas, Garrett and Bernstein, Jacob and Buie, Nicole and Rumbach, Anna F and Simonyan, Kristina},
title = {Brain–Computer Interface Improves Symptoms of Isolated Focal Laryngeal Dystonia: A Single‐Blind Study},
journal = {Movement Disorders},
year = {2026},
doi = {10.1002/mds.70114}
}
EUVIMED